Stock Taper
SCREENER COMPARE ANY 2 STOCKS
KURA
KURA ONCOLOGY, INC.
NASDAQ
$12.66
▼ DOWN 3.95% (-0.52)

KEY STATISTICS

Market Cap$1.12 B
52w High$13.90
52w Low$7.36
Dividend Yield—
Frequency—
P/E-3.78
Volume1.81M
Shares Out.88.77M

COMPANY

LEADERSHIP

Troy Edward Wilson
CHIEF EXECUTIVE
Troy Edward Wilson

COMPENSATION 2026

Salary$700,000
Stock Awards$0
Incentive Plan Pay$630,000
All Other Comp.$107,766
Total$4,735,016

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 16, 2015
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
260

PRICE TARGET

Target High$24.00
Target Low$15.00
Target Median$24.00
Target Consensus$22.89

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.$24.33M
NOV
3
TUE

PRICE

$12.66 ▼ DOWN 3.95% (−$0.52)
$12.75$12.90$13.059:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM12.66

About Kura Oncology, Inc.

https://kuraoncology.com ↗

Kura Oncology, a San Diego-based clinical-stage biopharmaceutical company, develops cancer treatments, including menin inhibitor ziftomenib and farnesyl transferase inhibitor tipifarnib, with ongoing clinical trials and collaborations like Novartis.

INDUSTRY

Biotechnology

A PRODUCT KURA ONCOLOGY, INC. IS KNOWN FOR

Komzifti (ziftomenib)
Komzifti (ziftomenib)

Komzifti (ziftomenib) is an FDA-approved, oral, selective menin inhibitor for relapsed/refractory NPM1-mutant AML, marking Kura Oncology's transition to a commercial-stage company with its leading therapeutic product.

COMPETITORS

COMPETITOR
BMEA COMPARE
JNJ COMPARE
SNDX COMPARE

Revenue by Products

IconPRODUCTQ2-2025Q1-2026Q2-2026
Operating Segments$15.29M — —
Collaboration Revenue— $12.5M $11.75M ▼
Product— $5.77M $9.12M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
132
LISTED HERE
23
RANKED BY POSITION SIZE
XBI
0.36% · 3.3M
VTI
0.00% · 2.8M
IWM
0.04% · 2.2M
FESM
0.10% · 501.1K
SCHA
0.02% · 422.3K
CANC
1.03% · 171.4K
BBP
1.79% · 161.8K
DFMC
0.03% · 157.3K
PRFZ
0.07% · 144.4K
LABU
0.25% · 119.2K
SBIO
0.58% · 109.9K
XRSU.L
0.04% · 79.5K
GSSC
0.08% · 69.5K
HAPS
0.44% · 59.8K
RSSL
0.04% · 40.4K
RFLR
0.18% · 13.6K
TILT
0.01% · 12.7K
URTY
0.01% · 3.5K
VETS
0.06% · 2.1K
AVSC
0.00% · 861
USUE.DE
0.00% · 341
RESM
0.04% · 169
RGSC.L
0.29% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
73.98%
HOLDERS
322
TOP 12 OF 322 · RANKED BY POSITION SIZE
Blackrock, Inc.
10.5M sh · $115.29M
Bvf Inc/Il
8.6M sh · $89.53M
Suvretta Capital Management, LLC
8.6M sh · $94.07M
Blackrock Inc.
7.0M sh · $143.43M
Armistice Capital, LLC
6.2M sh · $35.77M
Vanguard Group Inc
5.5M sh · $57.22M
State Street Corp
5.3M sh · $58.46M
Prosight Management, LP
3.4M sh · $27.29M
Aqr Capital Management LLC
3.1M sh · $34.3M
Deep Track Capital, LP
2.6M sh · $21.49M
Goldman Sachs Group Inc
2.6M sh · $23.14M
Geode Capital Management, LLC
2.2M sh · $24.47M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book1
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Chris Jacobs
Chris Jacobs
Purchase
2022-12-12
 Christopher L. Jacobs
Christopher L. Jacobs
Purchase
2022-12-12

INSIDER TRADES

★
DIRECTOR, OFFICER: PRESIDENT AND CEO
WILSON TROY EDWARD
Purchase · 100.0K shares
2026-08-24
★
OFFICER: CHIEF COMMERCIAL OFFICER
Powl Brian T.
Sale · 4.3K shares
2026-08-21
★
OFFICER: CHIEF LEGAL OFFICER
Bair Teresa Brophy
Sale · 31.5K shares
2026-08-19
★
DIRECTOR, OFFICER: PRESIDENT AND CEO
WILSON TROY EDWARD
Purchase · 100.0K shares
2026-08-17

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 3
MARKET OUTPERFORM 2
BUY 2
OVERWEIGHT 1
8 GRADES IN THE LAST 12 MONTHS
Citizens MARKET OUTPERFORM Wedbush OUTPERFORM Mizuho OUTPERFORM UBS BUY Leerink Partners OUTPERFORM HC Wainwright & Co. BUY Barclays OVERWEIGHT JMP Securities MARKET OUTPERFORM

SECTORS PEERS

PEERPRICE
TNGX$23.34COMPARE
BCAX$23.43COMPARE
TYRA$24.94COMPARE
REPL$15.50COMPARE
MRVI$7.68COMPARE
SVRA$5.26COMPARE
PRME$3.61COMPARE
RZLT$4.62COMPARE